On November 8, 2018 Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, reported that it will be presenting data at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting in Washington, D.C. from November 9-11, 2018 (Press release, Actym Therapeutics, NOV 8, 2018, View Source [SID1234530898]). The presentation is titled "STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing data demonstrating the potent anti-tumor activity of our first-in-class STING pathway agonist therapy, STACT-TREX1, in preclinical models. We are encouraged by the data showing that single-agent treatment with STACT-TREX1 generates tumor antigen-specific CD8+ T cell responses, suggesting induction of adaptive anti-tumor immunity after intravenous administration in mice. We believe this mechanism for activating the STING pathway in the tumor microenvironment represents a novel and superior approach for the treatment of cancer," said Dr. Christopher Thanos, President and CEO of Actym Therapeutics.
Details of the presentation are as follows:
Abstract
P235:
STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models
Date:
November 9, 2018
Location:
Hall E, Walter E. Washington Convention Center
For those unable to attend the conference who would like a copy of the presentation, please send an email request to [email protected]. Please include your name, company, title and phone number. The presentation will be emailed to those making proper requests after November 10, 2018.